Canada markets closed

Nestlé S.A. (NSRGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
106.44-2.04 (-1.88%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close108.48
Open106.81
Bid0.00 x 0
Ask0.00 x 0
Day's Range106.25 - 109.38
52 Week Range103.75 - 143.92
Volume5,750
Avg. Volume13,488
Market Cap296.295B
Beta (5Y Monthly)0.26
PE Ratio (TTM)17.65
EPS (TTM)6.03
Earnings DateN/A
Forward Dividend & Yield3.00 (2.77%)
Ex-Dividend DateApr 11, 2022
1y Target EstN/A
  • The Guardian

    Quality Street axes plastic wrappers for recyclable paper

    Nestlé says change after 86 years will keep 2bn wrappers a year out of landfill

  • Bloomberg

    Nestlé Says It Will Drop Palm Oil Supplier Accused of Abuses

    (Bloomberg) -- Nestlé SA has pledged to cut ties with an Indonesian palm oil supplier accused of land-rights abuses and environmental harm.Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMeta to Cut Headcount for First Time, Slash Budgets Across TeamsStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite HurricaneTop Apple Executive Is Leaving After Making Crude Remarks in TikTok

  • GlobeNewswire

    Cerecin closes Series IIB financing to advance CER-0001 clinical programs and build pipeline in neuro-metabolism drug development

    Series IIB Financing was supported by existing and new investors in South Korea.Proceeds strengthen Cerecin’s operating position to advance the clinical studies of CER-0001 in migraine and infantile spasms.New funds will also be used to build Cerecin’s pipeline and advance plans for a pivotal trial in Alzheimer’s disease. SINGAPORE and DENVER, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cerecin Inc., a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced it has su